Abstract:Background Spatial architecture within the tumor microenvironment (TME) can potentially impact disease pathology, progression and treatment response of DLBCL. Additionally, activation of host's immune system greatly determines response to immunotherapy treatments. Multiplex imaging using fluorescence immunohistochemistry (FIHC) has found to enable characterization and quantification of tissue-specific proteins involved in immune activation, which in turn have enabled identification of distinct cell types, their functional status, and their organization in TME. We developed and validated two complementary quantitative multiplex fluorescence IHC (mFIHC) panels using hypothesis-driven spatial profiling algorithms (Automated Quantitative Analysis known as AQUA® Technology) to evaluate T and B cell populations and their functional status to generate detailed spatial information of tumor microenvironment of DLBCL. mFIHC assays when combined with the use of AQUA® Technology were able to predict immunotherapies in a systematic meta-analysis of over 8000 patients treated with PD1/L1 pathway blockers.1 Implementation of mFIHC assays coupled with robust image analysis may assist in risk stratification of patients or enable efficacy assessment of immunomodulating cancer therapies. Methods We designed two novel mFIHC assays to (1) characterize various T (CD2, CD3, CD8, CD28) and B cell populations (CD2, CD3, CD19, PAX5), and (2) evaluate T cell functional status (CD8, Granzyme B, PD1). We successfully validated clinical grade mFIHC assays using automated staining (Leica Bond RX), imaging (PhenoImager HT) and analysis (AQUA® Technology) workflow. Results Sensitivity, accuracy and specificity were confirmed for all mFIHC assays on known positive and negative controls. Excellent reproducibility (less than 35% CV) and precision were observed across instruments, operators and independent experiments for all markers. Between these two panels, over 200 unique parameters were evaluated. The prevalence of CD2, CD3, CD19, and PAX5 ranged from 20% to >90% positive for the DLBCL samples tested and were overall highly concordant with each other. Conclusions The validated mFIHC assays examined B and T cell antigen expression in DLBCL and their interaction with PAX5+ and CD58+ cells within the TME. Implementation of mFIHC assays coupled with robust image analysis may assist in risk stratification of patients or enable efficacy assessment of immunomodulating cancer therapies. These assays may be used to further understand the complex immune cell and tumor cell spatial biology in the context of clinical trials. Reference Lu, Steve, Julie E Stein, David L Rimm, Daphne W Wang, J Michael Bell, Douglas B Johnson, Jeffrey A Sosman, et al. 'Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis.' JAMA oncology 5. 2019;8:1195–1204.

Bright-Field Multiplex Immunohistochemistry Assay for Tumor Microenvironment Evaluation in Melanoma Tissues

Brightfield Multiplex Immunohistochemistry Assay for PD-L1 Evaluation in Challenging Melanoma Samples

Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma

Brightfield multiplex immunohistochemistry with multispectral imaging

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma

Multiplex Immunohistochemistry for Mapping the Tumor Microenvironment

Multiplex Immunohistochemistry and High-Throughput Image Analysis for Evaluation of Spatial Tumor Immune Cell Markers in Human Breast Cancer.

Multiplexed Imaging Mass Cytometry Reveals Distinct Tumor-Immune Microenvironments Linked to Immunotherapy Responses in Melanoma

Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment

Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence

Multiplex Immunohistochemical Analysis of the Spatial Immune Cell Landscape of the Tumor Microenvironment

Multiplex Immunofluorescence Tyramide Signal Amplification for Immune Cell Profiling of Paraffin-Embedded Tumor Tissues

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues

Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues

Mapping the single cell spatial immune landscapes of the melanoma microenvironment

51 Tissue-based Spatial Analysis of DLBCL Tumor Microenvironment Using Multiplex Immunofluorescence AQUA® (automated Quantitative Analyses) Algorithms

Quantitative multiplex immunohistochemistry reveals inter-patient lymphovascular and immune heterogeneity in primary cutaneous melanoma

Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment

In-Depth Immune-Oncology Studies of the Tumor Microenvironment in a Humanized Melanoma Mouse Model

Immunoprofiling in Breast Cancer Microenvironment with Multiplexed Immunofluorescence

Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue